Introduction: Idecabtagene vicleucel (Ide-Cel) and ciltacabtagene autoleucel (Cilta-cel) are novel CAR-T therapies targeting B-cell maturation antigen (BCMA) and approved for relapsed and refractory ...

BAFF-R = BAFF receptor; BCMA = B-cell-maturation antigen; MS = multiple sclerosis; TACI = transmembrane activator and calcium modulator cytophilin ligand interactor. B cells are clonally expanded ...

First up is iMMagine-1, a pivotal phase 2 trial evaluating the BCMA-directed CAR-T among patients who'd received a median four lines of prior treatment. Even more recent results from the study ...

Carvykti followed Bristol Myers Squibb and 2Seventy bio’s Abecma onto the market. Like Abecma, it is a CAR-T therapy targeted to a protein called BCMA that’s commonly found on diseased multiple ...

1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Genetics, Yale University School of Medicine, New Haven, Connecticut.

1Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, Missouri. 2Center for Gene and Cellular Immunotherapy, Washington University School of Medicine ...

Notably, antibodies targeting G protein-coupled receptors (GPCRs) and ion channels, both of which are transmembrane proteins, are gaining increasing attention in drug development. Transmembrane ...

APTN-101 works by simultaneously targeting the EGFRvIII mutation, a variant commonly found in gliomas, and the CD3 receptor on T cells ... CND106 targets B-cell maturation antigen, while CND261 binds ...